Friday, November 25, 2005 1:27:31 PM
I agree that 50% downside is not a lot for this type of company. However, this comes after 90% drop from the high. Since only a small profit has been made during the quarter it seems to me that the explanation for the booked value is that the sharecount has increased substantially during the quarter. This will only come to light next quarter because the sharecount is based on some kind of average during a certain period and not the end of the quarter. I therefore think shareholders are in for a nasty surprise when it comes to the sharecount if they are not aware of the above.
Recent FITY News
- Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health • ACCESS Newswire • 04/15/2026 12:30:00 PM
- Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market • ACCESS Newswire • 04/14/2026 12:30:00 PM
- Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace • GlobeNewswire Inc. • 01/05/2026 06:08:59 PM
- Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace • InvestorsHub NewsWire • 01/05/2026 06:00:00 PM
- Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer • GlobeNewswire Inc. • 10/09/2025 02:23:35 PM
- Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer • InvestorsHub NewsWire • 10/09/2025 02:00:00 PM
- Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc. • GlobeNewswire Inc. • 09/30/2025 01:56:45 PM
- Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc. • InvestorsHub NewsWire • 09/30/2025 01:45:00 PM
- Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB • GlobeNewswire Inc. • 09/23/2025 01:07:25 PM
- Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB • InvestorsHub NewsWire • 09/23/2025 12:35:36 PM
- Fifty1 Labs, Inc. Leadership Publishes Landmark Framework to Unlock Global Oncology Data Through AI-Driven Real-World Evidence • InvestorsHub NewsWire • 09/04/2025 12:30:00 PM
- Fifty1 Labs Partners with LUNR Aerospace to Pioneer AI-Driven Drug Repurposing for Space Medicine, Strategic Collaboration Aims to Harness AI and Orbital Access to Revolutionize Astronaut Health Solutions in a $2 Billion Market by 2032 • InvestorsHub NewsWire • 08/26/2025 01:00:00 PM
- Fifty1 Labs, Inc. Subsidiary Fifty1 AI Labs Partners with ViRx@Stanford Under 'BE READI!' Initiative to Advance AI-Powered Antiviral Drug Repurposing • InvestorsHub NewsWire • 08/22/2025 02:30:00 PM
- Fifty1 Labs, Inc. and BioSpark AI Unlock 2,000+ Real-World Treatment Pathways to Accelerate Functional Medicine Innovation • InvestorsHub NewsWire • 08/12/2025 12:30:00 PM
- Fifty 1 Labs, Inc. Hosts Successful Virtual Shareholder Teleconference, Showcasing AI-Driven Functional Medicine Strategy and World-Class Leadership • InvestorsHub NewsWire • 07/29/2025 01:00:00 PM
- Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières • InvestorsHub NewsWire • 07/28/2025 12:30:00 PM
- Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies • InvestorsHub NewsWire • 07/17/2025 12:30:00 PM
- Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • InvestorsHub NewsWire • 07/10/2025 12:30:49 PM
- Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • InvestorsHub NewsWire • 07/08/2025 12:30:00 PM
